NO20024179L - Humane antistoffer mot eotaksin og deres anvendelse - Google Patents

Humane antistoffer mot eotaksin og deres anvendelse

Info

Publication number: NO20024179L
Authority: NO; Norway
Prior art keywords: eotaxin; cat; specific binding; human; human antibodies
Prior art date: 2000-03-03

Application number

NO20024179A

Other languages

English (en)

Other versions

NO20024179D0 (no

Inventor

Tristan John Vaughan

Alison Jane Wilton

Stephen Smith

Original Assignee

Cambridge Antibody Tech

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-03

Filing date

2002-09-02

Publication date

2002-11-01

2002-09-02 Application filed by Cambridge Antibody Tech filed Critical Cambridge Antibody Tech

2002-09-02 Publication of NO20024179D0 publication Critical patent/NO20024179D0/no

2002-11-01 Publication of NO20024179L publication Critical patent/NO20024179L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Dermatology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Otolaryngology (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

NO20024179A 2000-03-03 2002-09-02 Humane antistoffer mot eotaksin og deres anvendelse NO20024179L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US18724600P	2000-03-03	2000-03-03
PCT/GB2001/000927 WO2001066754A1 (en)	2000-03-03	2001-03-02	Human antibodies against eotaxin and their use

Publications (2)

Publication Number	Publication Date
NO20024179D0 NO20024179D0 (no)	2002-09-02
NO20024179L true NO20024179L (no)	2002-11-01

Family

ID=22688187

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20024179A NO20024179L (no)	2000-03-03	2002-09-02	Humane antistoffer mot eotaksin og deres anvendelse

Country Status (14)

Country	Link
US (6)	US7323311B2 (no)
EP (1)	EP1259615B1 (no)
JP (1)	JP5198704B2 (no)
AT (1)	ATE414151T1 (no)
AU (1)	AU778392B2 (no)
BR (1)	BRPI0108923B8 (no)
CA (1)	CA2401342C (no)
DE (1)	DE60136527D1 (no)
GB (1)	GB2361704C (no)
IL (2)	IL151499A0 (no)
MX (1)	MXPA02008472A (no)
NO (1)	NO20024179L (no)
NZ (1)	NZ521182A (no)
WO (1)	WO2001066754A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ521182A (en)	2000-03-03	2004-11-26	Cambridge Antibody Tech	Human antibodies against eotaxin comprising VH adn VL domains and their use
EP2383290B1 (en)	2001-08-23	2019-05-08	Rsr Limited	Epitope regions of a thyrotropin (tsh) receptor, uses thereof and antibodies thereto
EP1608316A4 (en) *	2003-03-24	2007-08-15	Mercia Pharma Inc	METHOD AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY CONDITIONS
GB0407315D0 (en)	2003-07-15	2004-05-05	Cambridge Antibody Tech	Human antibody molecules
EP1850873B1 (en)	2005-02-08	2018-11-28	Genzyme Corporation	Antibodies to tgfbeta
US20070099239A1 (en) *	2005-06-24	2007-05-03	Raymond Tabibiazar	Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
WO2007036745A2 (en)	2005-09-30	2007-04-05	Medimmune Limited	Interleukin-13 antibody composition
CA2647449C (en)	2006-03-27	2017-05-16	Medimmune Limited	Binding member for gm-csf receptor
NZ621170A (en)	2009-05-13	2015-08-28	Genzyme Corp	Anti-human cd52 immunoglobulins
US8176867B2 (en)	2009-05-28	2012-05-15	Richard J. A. Gayton	Watercraft immobilizing system
WO2012022734A2 (en)	2010-08-16	2012-02-23	Medimmune Limited	Anti-icam-1 antibodies and methods of use
CA2818548A1 (en)	2010-11-19	2012-05-24	Toshio Imai	Neutralizing anti-ccl20 antibodies
US20130261153A1 (en) *	2012-04-03	2013-10-03	Boehringer Ingelheim International Gmbh	Use of ccr3-inhibitors
US10064945B2 (en)	2012-05-11	2018-09-04	Gruenenthal Gmbh	Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US20140271666A1 (en) *	2013-03-14	2014-09-18	Immune Pharmaceuticals Ltd.	Use of anti-eotaxin antibodies for treating inflammatory bowel disease
AR095199A1 (es)	2013-03-15	2015-09-30	Genzyme Corp	Anticuerpos anti-cd52
EP3613435A1 (en)	2015-01-28	2020-02-26	Universite De Bordeaux	Chemokine receptor cxcr4 inhibitors for treating and/or preventing chronic obstructive pulmonary disease
HUE053097T2 (hu)	2015-03-31	2021-06-28	Medimmune Ltd	Új IL33 forma, IL33 mutáltatott formái, ellenanyagok, vizsgálati eljárások és eljárások azok alkalmazására
CA3010224A1 (en)	2016-01-22	2017-07-27	Merck Sharp & Dohme Corp.	Anti-coagulation factor xi antibodies
EP4000632A1 (en)	2016-06-02	2022-05-25	MedImmune Limited	Antibodies to alpha-synuclein and uses thereof
WO2017212488A1 (en) *	2016-06-06	2017-12-14	Hadasit Medical Research Service And Development Ltd.	Anti-eotaxin for immunoprotection and hepatoprotection
EA201892716A1 (ru)	2016-06-14	2019-05-31	Мерк Шарп И Доум Корп.	Антитела к фактору свертывания xi
TW202519263A (zh) *	2019-03-21	2025-05-16	美商再生元醫藥公司	含有抗il-33抗體之穩定調配物
US12221463B2 (en)	2020-08-07	2025-02-11	The Board Of Regents Of The University Of Oklahoma	Method of promoting wound healing by inhibiting CCR3
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8925590D0 (en)	1989-11-13	1990-01-04	Central Blood Lab Authority	Monoclonal antibodies
JP3502093B2 (ja) *	1991-07-15	2004-03-02	ザ・ウエルカム・ファウンデーション・リミテッド	抗体の製造
IL103758A (en)	1991-12-13	1998-07-15	Akzo Nv	Tumor specific monoclonal antibodies
JPH09507211A (ja)	1993-09-14	1997-07-22	ナショナルハートアンドラングインスティチュート	エオタキシン：好酸球走化性サイトカイン
US6403782B1 (en)	1995-06-22	2002-06-11	President And Fellows Of Harvard College	Nucleic acid encoding eotaxin
US7265201B1 (en) *	1995-06-23	2007-09-04	Millennium Pharmaceuticals, Inc.	Human chemotactic cytokine
WO1997012914A1 (en)	1995-10-05	1997-04-10	Shionogi & Co., Ltd.	Novel human cc chemokine
WO1999010534A1 (en)	1997-08-22	1999-03-04	Center For Blood Research, Inc.	Diagnosis and treatment of diseases with eotaxin and antagonists and agonists thereof
GB9809951D0 (en) *	1998-05-08	1998-07-08	Univ Cambridge Tech	Binding molecules
WO1999066951A2 (en) *	1998-06-22	1999-12-29	Immunomedics, Inc.	Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6492497B1 (en) *	1999-04-30	2002-12-10	Cambridge Antibody Technology Limited	Specific binding members for TGFbeta1
CN1371416B (zh) *	1999-08-24	2012-10-10	梅达里克斯公司	人ctla-4抗体及其应用
NZ521182A (en)	2000-03-03	2004-11-26	Cambridge Antibody Tech	Human antibodies against eotaxin comprising VH adn VL domains and their use
US6946546B2 (en)	2000-03-06	2005-09-20	Cambridge Antibody Technology Limited	Human antibodies against eotaxin
GB0016138D0 (en)	2000-06-30	2000-08-23	Novartis Ag	Organic compounds

2001
- 2001-03-02 NZ NZ521182A patent/NZ521182A/en not_active IP Right Cessation
- 2001-03-02 GB GB0105237A patent/GB2361704C/en not_active Expired - Lifetime
- 2001-03-02 AT AT01907990T patent/ATE414151T1/de not_active IP Right Cessation
- 2001-03-02 CA CA2401342A patent/CA2401342C/en not_active Expired - Lifetime
- 2001-03-02 IL IL15149901A patent/IL151499A0/xx unknown
- 2001-03-02 EP EP01907990A patent/EP1259615B1/en not_active Expired - Lifetime
- 2001-03-02 WO PCT/GB2001/000927 patent/WO2001066754A1/en not_active Ceased
- 2001-03-02 US US10/220,418 patent/US7323311B2/en not_active Expired - Lifetime
- 2001-03-02 AU AU35852/01A patent/AU778392B2/en not_active Expired
- 2001-03-02 BR BR0108923A patent/BRPI0108923B8/pt not_active IP Right Cessation
- 2001-03-02 JP JP2001565908A patent/JP5198704B2/ja not_active Expired - Lifetime
- 2001-03-02 MX MXPA02008472A patent/MXPA02008472A/es unknown
- 2001-03-02 DE DE60136527T patent/DE60136527D1/de not_active Expired - Lifetime
2002
- 2002-08-27 IL IL151499A patent/IL151499A/en active IP Right Grant
- 2002-09-02 NO NO20024179A patent/NO20024179L/no not_active Application Discontinuation
2007
- 2007-12-17 US US11/958,210 patent/US8067564B2/en not_active Expired - Fee Related
2011
- 2011-10-19 US US13/277,132 patent/US8715961B2/en not_active Expired - Lifetime
2014
- 2014-03-24 US US14/223,561 patent/US9284589B2/en not_active Expired - Fee Related
2016
- 2016-02-03 US US15/014,945 patent/US10577413B2/en not_active Expired - Fee Related
2020
- 2020-09-03 US US17/011,379 patent/US20210277103A1/en not_active Abandoned

Also Published As

Publication number	Publication date
GB2361704B (en)	2002-04-10
EP1259615B1 (en)	2008-11-12
DE60136527D1 (de)	2008-12-24
US10577413B2 (en)	2020-03-03
BR0108923A (pt)	2003-04-22
JP5198704B2 (ja)	2013-05-15
US20040014132A1 (en)	2004-01-22
WO2001066754A1 (en)	2001-09-13
AU3585201A (en)	2001-09-17
JP2003528598A (ja)	2003-09-30
US20210277103A1 (en)	2021-09-09
US20080182319A1 (en)	2008-07-31
ATE414151T1 (de)	2008-11-15
MXPA02008472A (es)	2004-03-26
CA2401342A1 (en)	2001-09-13
EP1259615A1 (en)	2002-11-27
US9284589B2 (en)	2016-03-15
US8715961B2 (en)	2014-05-06
US20140294857A1 (en)	2014-10-02
NZ521182A (en)	2004-11-26
GB0105237D0 (en)	2001-04-18
CA2401342C (en)	2010-08-03
BRPI0108923B8 (pt)	2021-05-25
NO20024179D0 (no)	2002-09-02
IL151499A (en)	2010-06-30
IL151499A0 (en)	2003-04-10
BRPI0108923B1 (pt)	2018-11-13
US7323311B2 (en)	2008-01-29
AU778392B2 (en)	2004-12-02
US8067564B2 (en)	2011-11-29
US20160257741A1 (en)	2016-09-08
US20120270265A1 (en)	2012-10-25
GB2361704A (en)	2001-10-31
GB2361704C (en)	2006-08-02

Publication	Publication Date	Title
NO20024179L (no)	2002-11-01	Humane antistoffer mot eotaksin og deres anvendelse
LU93274I2 (fr)	2016-12-27	Elotuzumab
DE60031279D1 (de)	2006-11-23	Humane monoklonale antikörper gegen prostata spezifisches membranantigen
DK1425389T3 (da)	2012-01-30	Interleukin-15-(IL-15)-specifikke humane antistoffer
DK3284753T3 (da)	2021-07-05	Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose
CY1113489T1 (el)	2016-04-13	Αντισωμα το οποιο δεσμευει αλφα4βητα7 ιντεγκρινη και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
DE60040301D1 (de)	2008-10-30	Humane monoklonale antikörper gegen den tgf-beta ii rezeptor und dessen medizinische verwendung
WO2004043989A3 (en)	2004-10-21	Human monoclonal antibodies to heparanase
ATE482722T1 (de)	2010-10-15	Therapeutische verwendung von anti-cs1- antikörpern
CY1113182T1 (el)	2016-04-13	Συνθεσεις και μεθοδοι για την αντιμετωπιση ιογενους λοιμωξης
BR0011838B1 (pt)	2012-06-26	elemento de sela e estrutura de misturador estático.
NO20026063D0 (no)	2002-12-17	Antistoffer mot human MCP-1
ATE373719T1 (de)	2007-10-15	Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
PL401886A1 (pl)	2013-05-27	Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
DE60328195D1 (de)	2009-08-13	Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
WO2002059154A3 (en)	2003-10-09	Neutralizing human monoclonal antibodies against hiv-1, their production and uses
WO2002020619A3 (en)	2003-01-23	HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)
DK1196188T3 (da)	2005-11-07	VGF-selektive monoklonale antistoffer og deres anvendelse til behandling af VGF-relaterede lidelser
WO2002011549A3 (en)	2002-08-22	Treatment of mycobacterial infection
ATE372349T1 (de)	2007-09-15	Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
TH64455A (th)	2004-10-05	สารภูมิต้านทาน mcp-1 ในมนุษย์

Legal Events

Date	Code	Title	Description
2009-10-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application